First Trimester Prediction of Adverse Pregnancy Outcomes-Identifying Pregnancies at Risk from as Early as 11-13 Weeks.

11–13 weeks chromosomal abnormalities fetal growth restriction first trimester gestational diabetes placenta accreta spectrum preeclampsia pregnancy outcomes preterm birth small for gestational age structural defects

Journal

Medicina (Kaunas, Lithuania)
ISSN: 1648-9144
Titre abrégé: Medicina (Kaunas)
Pays: Switzerland
ID NLM: 9425208

Informations de publication

Date de publication:
22 Feb 2022
Historique:
received: 25 01 2022
revised: 18 02 2022
accepted: 21 02 2022
entrez: 26 3 2022
pubmed: 27 3 2022
medline: 1 4 2022
Statut: epublish

Résumé

There is consistent evidence that many of the pregnancy complications that occur late in the second and third trimester can be predicted from an integrated 11-13 weeks visit, where a maternal and fetal assessment are comprehensively performed. The traditional aims of the 11-13 weeks visit have been: establishing fetal viability, chorionicity and dating of the pregnancy, and performing the combined screening test for common chromosomal abnormalities. Recent studies have shown that the first trimester provides important information that may help to predict pregnancy complications, such as preeclampsia and fetal growth restriction, stillbirth, preterm birth, gestational diabetes mellitus and placenta accreta spectrum disorder. The aim of this manuscript is to review the methods available to identify pregnancies at risk for adverse outcomes after screening at 11-13 weeks. Effective screening in the first trimester improves pregnancy outcomes by allowing specific interventions such as administering aspirin and directing patients to specialist clinics for regular monitoring.

Identifiants

pubmed: 35334508
pii: medicina58030332
doi: 10.3390/medicina58030332
pmc: PMC8951779
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Références

Diabetes. 2010 Dec;59(12):3017-22
pubmed: 20876721
Ultrasound Obstet Gynecol. 2019 Jan;53(1):101-106
pubmed: 30199114
Ultrasound Obstet Gynecol. 2018 Jul;52(1):52-59
pubmed: 29704277
N Engl J Med. 2017 Aug 17;377(7):613-622
pubmed: 28657417
Fetal Diagn Ther. 2015;38(1):14-21
pubmed: 25531073
Ultrasound Obstet Gynecol. 2009 Mar;33(3):259-64
pubmed: 19248005
Ultrasound Obstet Gynecol. 2016 Nov;48(5):613-617
pubmed: 27561595
Ultrasound Obstet Gynecol. 2018 Feb;51(2):169-175
pubmed: 28661021
Ultrasound Obstet Gynecol. 2016 Nov;48(5):618-623
pubmed: 27854388
Fetal Diagn Ther. 2011;29(3):183-96
pubmed: 21389681
Am J Obstet Gynecol. 2020 Jul;223(1):12-23.e7
pubmed: 31733203
Ultrasound Obstet Gynecol. 2020 Sep;56(3):400-407
pubmed: 32441401
Prenat Diagn. 2011 Jan;31(1):75-83
pubmed: 21210482
Ultrasound Obstet Gynecol. 2022 Jan;59(1):61-68
pubmed: 34643306
N Engl J Med. 2007 Aug 2;357(5):462-9
pubmed: 17671254
Ultrasound Obstet Gynecol. 2006 Oct;28(5):637-43
pubmed: 16952214
Clin Chem. 2011 Apr;57(4):609-13
pubmed: 21325104
Prenat Diagn. 2011 Feb;31(2):135-41
pubmed: 21268030
Fetal Diagn Ther. 2012;31(3):154-61
pubmed: 22399065
Ultrasound Obstet Gynecol. 2009 May;33(5):512-7
pubmed: 19338027
Ultrasound Obstet Gynecol. 2009 Jan;33(1):18-22
pubmed: 19031473
Ultrasound Obstet Gynecol. 2021 Mar;57(3):392-400
pubmed: 32936500
Ultrasound Obstet Gynecol. 2018 Jun;51(6):743-750
pubmed: 29536574
Ultrasound Obstet Gynecol. 2021 Jan;57(1):52-61
pubmed: 33094535
Ultrasound Obstet Gynecol. 2010 Oct;36(4):404-11
pubmed: 20658511
Ultrasound Obstet Gynecol. 2019 Oct;54(4):468-476
pubmed: 31408229

Auteurs

Alexandra Bouariu (A)

Department of Obstetrics and Gynecology, Filantropia Clinical Hospital, 011171 Bucharest, Romania.

Anca Maria Panaitescu (AM)

Department of Obstetrics and Gynecology, Filantropia Clinical Hospital, 011171 Bucharest, Romania.
Division of Physiology and Neuroscience, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.

Kypros H Nicolaides (KH)

Harris Birthright Research Centre of Fetal Medicine, King's College Hospital, London SE5 8BB, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH